Legendary investors such as Leon Cooperman and Seth Klarman earn enormous amounts of money for themselves and their investors by doing in-depth research on small-cap stocks that big brokerage houses don’t publish. Small cap stocks -especially when they are screened well- can generate substantial outperformance versus a boring index fund. That’s why we analyze the activity of those elite funds in these small-cap stocks. In the following paragraphs, we analyze Haemonetics Corporation (NYSE:HAE) from the perspective of those elite funds.
Haemonetics Corporation (NYSE:HAE) investors should be aware of an increase in enthusiasm from smart money recently. HAE was in 11 hedge funds’ portfolios at the end of September. There were 10 hedge funds in our database with HAE positions at the end of the previous quarter. At the end of this article we will also compare HAE to other stocks including Yelp Inc (NYSE:YELP), Knowles Corp (NYSE:KN), and 51job, Inc. (ADR) (NASDAQ:JOBS) to get a better sense of its popularity.
Now, let’s view the latest action surrounding Haemonetics Corporation (NYSE:HAE).
How are hedge funds trading Haemonetics Corporation (NYSE:HAE)?
Heading into Q4, a total of 11 of the hedge funds tracked by Insider Monkey held long positions in this stock, a change of 10% from one quarter earlier. With the smart money’s capital changing hands, there exists a select group of notable hedge fund managers who were upping their holdings significantly (or already accumulated large positions).
According to Insider Monkey’s hedge fund database, Jim Simons’s Renaissance Technologies has the biggest position in Haemonetics Corporation (NYSE:HAE), worth close to $8.4 million, accounting for less than 0.1%% of its total 13F portfolio. The second most bullish fund manager is Millennium Management, managed by Israel Englander, which holds a $8 million position; the fund has less than 0.1%% of its 13F portfolio invested in the stock. Remaining members of the smart money with similar optimism encompass Ken Fisher’s Fisher Asset Management, Bill Miller’s Legg Mason Capital Management and Peter Rathjens, Bruce Clarke and John Campbell’s Arrowstreet Capital.